Enhertu strikes again with a PhIII success in another breast cancer population
Another summer day, another Enhertu update.
The AstraZeneca-Daiichi Sankyo antibody-drug conjugate has passed another trial, this time a Phase III trial testing the cancer drug versus physician’s choice in patients with HER2-positive metastatic breast cancer.
The DESTINY-Breast02 study beat out the other treatments — trastuzumab/capecitabine or lapatinib/capecitabine — in improving progression-free survival and a secondary endpoint, overall survival.
Following a landmark data drop at ASCO earlier this summer, Enhertu has gone on a winning streak, including two label expansions this month — HER2-low metastatic breast cancer and previously treated HER2-mutant metastatic non-small cell lung cancer.
The UK Big Pharma did not disclose any other details of the approximately 600-patient trial, other than saying no new safety concerns popped up, consistent with previous late-stage trials of the drug.
“Interstitial lung disease (ILD) rates and severity were consistent with those observed in other metastatic breast cancer trials of Enhertu, with a low rate of Grade 5 ILD events observed as determined by an independent adjudication committee,” the company said in its release.
“As this is the confirmatory trial for our current breast cancer indication in Europe and several other countries, we look forward to sharing these findings with regulatory authorities to add to the body of data for Enhertu for the treatment of HER2-positive metastatic breast cancer,” Daiichi Sankyo global head of R&D Ken Takeshita said in a statement.
The news comes just days after Daiichi Sankyo cleared a major litigation hurdle, with Seagen losing an arbitration dispute with the company over its ADC tech.